Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference
Tweet
Share
E-mailADELAIDE, Australia, June 27, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Dr. Errol De Souza, Executive Chairman of Bionomics, will participate in a fireside chat at the First Annual H.C. Wainwright Mental Health Conference taking place virtually and in-person in New York on June 27, 2022.
An audio webcast link for the event, when available, will be posted to Bionomics’ website in the Investors-Events and Presentations section.
FOR FURTHER INFORMATION PLEASE CONTACT:
| Investor RelationsMr. Connor BernsteinVice President, Strategy and Corporate Development+1 (650) 524-5143[email protected] | Investor RelationsKevin Gardner[email protected] |
About Bionomics Limited
Bionomics (ASX:BNO, NASDAQ: BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious CNS disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- CorelDRAW 2026 Review: New Features and Workflow Updates for Designers and Print Professionals Highlighted by Expert Consumers
- 40 Acres And A Profit Launches The Levi Bean Lake Real Estate Course Built on Real Houses and $1M+ in Capital
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
